Zobrazeno 1 - 10
of 12
pro vyhledávání: '"M C, Miggiano"'
Autor:
A. Iurlo, D. Cattaneo, D. Consonni, F. Castagnetti, M. C. Miggiano, G. Binotto, M. Bonifacio, G. Rege-Cambrin, M. Tiribelli, F. Lunghi, A. Gozzini, P. Pregno, E. Abruzzese, I. Capodanno, C. Bucelli, M. Pizzuti, S. Artuso, M. Iezza, E. Scalzulli, G. La Barba, A. Maggi, S. Russo, C. Elena, A. R. Scortechini, A. Tafuri, R. Latagliata, G. Caocci, M. Bocchia, S. Galimberti, L. Luciano, C. Fava, R. Foà, G. Saglio, G. Rosti, M. Breccia
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
TKIs long-term treatment in CML may lead to persistent adverse events (AEs) that can promote relevant morbidity and mortality. Consequently, TKIs dose reduction is often used to prevent AEs. However, data on its impact on successful treatment-free re
Externí odkaz:
https://doaj.org/article/b301c0dcb99740a68845aace603611d1
Autor:
F. Efficace, F. Cottone, B. Yanez, F. Castagnetti, G. Caocci, M. Bonifacio, A. Patriarca, I. Capodanno, M. C. Miggiano, M. Tiribelli, M. Breccia, L. Luciano, V. Giai, A. Iurlo, E. Abruzzese, C. Fava, G. Rosti, J. Cortes, V. Kota, M. Vignetti, D. Cella
Publikováno v:
HemaSphere, Vol 6, Pp 1587-1588 (2022)
Externí odkaz:
https://doaj.org/article/b79323a510be449393fd51578fbcb9b7
Autor:
N, Testoni, G, Martinelli, A, Zaccaria, M C, Miggiano, S, Pelliconi, G, Visani, S, Manfroi, F, Gherlinzoni, S, Mangianti, S, Tura
Publikováno v:
Bone marrow transplantation. 18(6)
Clonal chromosome aberrations observed in patients who have relapsed after autologous bone marrow transplantation (ABMT) are usually related to the cytogenetic abnormalities observed at diagnosis. In order to assess this relationship, we evaluated 30
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3d44ea7950425332892cd2086974e0d6
https://pubmed.ncbi.nlm.nih.gov/8971385
https://pubmed.ncbi.nlm.nih.gov/8971385
Autor:
Sante Tura, Filippo Gherlinzoni, M C Miggiano, Pier Luigi Zinzani, Alessandra Fortuna, Giuseppe Visani, Roberto M. Lemoli, Gianantonio Rosti
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 14(11)
PURPOSE To assess the safety, tolerability, and hematopoietic efficacy of sequential and concomitant administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human interleukin-3 (rhIL-3), to accelerate recon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b46ec391e33b672d7b51daa74cc674f
https://pubmed.ncbi.nlm.nih.gov/8918500
https://pubmed.ncbi.nlm.nih.gov/8918500
Autor:
F, Lauria, D, Raspadori, M A, Ventura, D, Rondelli, P L, Zinzani, F, Gherlinzoni, M C, Miggiano, M, Fiacchini, G, Rosti, S, Rizzi, S, Tura
Publikováno v:
Bone marrow transplantation. 18(1)
In order to induce a therapeutic immunomodulatory activity, 11 patients with high-grade non-Hodgkin's lymphoma (HG-NHL) at a median of 42 days after autologous bone marrow transplantation (ABMT) received recombinant interleukin-2 (rIL-2) subcutaneous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3cb516101e8b1db28b1dca92d43767bf
https://pubmed.ncbi.nlm.nih.gov/8831999
https://pubmed.ncbi.nlm.nih.gov/8831999
Autor:
M C, Miggiano, F, Gherlinzoni, G, Rosti, G, Bandini, G, Visani, M, Fiacchini, P, Ricci, N, Testoni, M R, Motta, A, Geromin, S, Rizzi, A, Belardinelli, S, Mangianti, S, Manfroi, S, Tura
Publikováno v:
Leukemia. 10(3)
We evaluated the role of ABMT in late 1st CR AML adult patients using busulfan plus cyclophosphamide as preparative regimen. Fifty-one adult patients (mean age 36 years, range 15-59) with AML underwent ABMT in 1st CR. Three of them had a prior diagno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::95c76526a234f9d8c52017aa33234c93
https://pubmed.ncbi.nlm.nih.gov/8642854
https://pubmed.ncbi.nlm.nih.gov/8642854
Autor:
Pl Tazzari, M. A. Ventura, Silvano Ferrini, D. Rondelli, Donatella Raspadori, Sante Tura, F. Lauria, M C Miggiano
Publikováno v:
Annals of hematology. 71(4)
Ten patients with high-grade non-Hodgkin's lymphoma (HG-NHL) entered a subcutaneous (s.c.) recombinant interleukin 2 (rIL2) trial within 2 months of undergoing autologous bone marrow transplantation (ABMT). Immunological studies, consisting in T- and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54aad9e17d373192c61d2d98b43ca6cf
https://pubmed.ncbi.nlm.nih.gov/7578523
https://pubmed.ncbi.nlm.nih.gov/7578523
Publikováno v:
Blood. 83(8)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c58a0658914c40429a62720a59d70f95
https://pubmed.ncbi.nlm.nih.gov/8161809
https://pubmed.ncbi.nlm.nih.gov/8161809
Autor:
L, Catani, L, Gugliotta, M, Mattioli Belmonte, N, Vianelli, F, Gherlinzoni, M C, Miggiano, A R, Belardinelli, G, Rosti, E, Calori, G, Bandini
Publikováno v:
Bone marrow transplantation. 12(3)
Severe thrombotic alterations, such as veno-occlusive disease of the liver, may occur in the early phase following high-dose chemoradiotherapy and BMT. In this study, performed in patients with hematological malignancies subjected to allogeneic (10 c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d79f1a8c52d7a8d433f67ddeafb6a814
https://pubmed.ncbi.nlm.nih.gov/8241985
https://pubmed.ncbi.nlm.nih.gov/8241985
Autor:
Nicoletta Testoni, Gianantonio Rosti, Maria Alessandra Santucci, Alfonso Zaccaria, M C Miggiano, Sante Tura, Celso B, Marina Buzzi, Angela Tassinari
Publikováno v:
Leukemia research. 15(5)
Allogeneic bone marrow transplantation is the only way to cure patients with Ph1+ chronic myeloid leukemia. It is commonly assumed that, in order to obtain a cure for the patients, the leukemic clone must be completely destroyed by the conditioning t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bc8f2e4b529183b0dd513cc4a724547
https://pubmed.ncbi.nlm.nih.gov/2046382
https://pubmed.ncbi.nlm.nih.gov/2046382